United States Patent 6,403,120: Scope, Claim Boundaries, and US Landscape
US Patent 6,403,120 claims a method of dosing venlafaxine hydrochloride using a specific extended-release (ER) formulation designed to deliver low peak venlafaxine plasma exposure (≤ ~150 ng/mL) over 24 hours, with reduced nausea and emesis.
What does US 6,403,120 claim, in operational terms?
Independent claim 1 defines a “dose + PK target + formulation type”
Claim 1 is a method for providing:
- Therapeutic blood plasma concentration of venlafaxine over 24 hours
- With diminished incidence of nausea and emesis
- By orally administering an extended release formulation that provides:
- Peak blood plasma levels of venlafaxine ≤ about 150 ng/mL
- Where the formulation contains venlafaxine hydrochloride as the active ingredient
Practical boundary: claim 1 is not just “ER venlafaxine.” It is ER venlafaxine with a measurable PK ceiling tied to nausea/emesis reduction.
Claims 2 and 13-14 add encapsulation/spheroid structure
- Claim 2: ER formulation is encapsulated
- Claim 13: ER formulation comprises venlafaxine HCl in a spheroid
- Claim 14: venlafaxine HCl in an encapsulated spheroid
Practical boundary: the “ER form” must be in (or within) an encapsulation context, and the drug is present as part of a spheroidal ER structure.
Claims 3-12 define the core spheroid composition and coating ranges
The ER mechanism is built around spheroids containing:
- Venlafaxine hydrochloride
- Microcrystalline cellulose (MCC), with optional hydroxypropylmethylcellulose (HPMC)
And coated with a specific film coating system:
- Ethyl cellulose, NF (EC)
- HPMC, USP (in coating)
Core spheroids (Claim 3)
- Spheroids comprised of:
- Venlafaxine hydrochloride
- Microcrystalline cellulose
- Optionally HPMC
Core spheroid quantitative limits (Claims 4, 6, 8, 10-12)
| Claim |
Venlafaxine HCl in spheroid (wt%) |
MCC in spheroid (wt%) |
Optional HPMC in spheroid (wt%) |
| 4 |
~6% to ~40% |
~50% to ~94% |
~0.25% to ~1% |
| 6 |
~30% to ~40% |
~50% to ~70% |
~0.25% to ~1% |
| 8 |
Co-allocated as “about 6% to about 30%” (see coating claim) and core defined as “~70.1% to ~94% MCC” |
~70.1% to ~94% |
~0.25% to ~1% |
| 10 |
“coated with” language but functional design indicates spheroid design space: 6% to 25% |
95% to 75% (allocation reversal in claim text) |
~0.25% to ~1% |
| 11 |
~6% to ~25% |
~94% to ~75% |
~0.25% to ~1% |
| 12 |
~6% to ~20% |
~94% to ~80% |
~0.25% to ~1% |
Practical boundary: the enforceable formulation is anchored to MCC-based spheroids with a small HPMC option, and venlafaxine loading is constrained into claim-embedded windows.
Film coating ranges (Claims 5, 7, 9)
Coating defined as:
- Total film coating: ~2% to ~12% of total formulation weight
- Film coating composition:
- ~80% to ~90% EC
- ~10% to ~20% HPMC (USP)
| Claim |
Total coating (wt% of formulation) |
EC wt% of coating |
HPMC wt% of coating |
| 5 |
~2% to ~12% |
~80% to ~90% |
~10% to ~20% |
| 7 |
~2% to ~12% |
~80% to ~90% |
~10% to ~20% |
| 9 |
~2% to ~12% |
~80% to ~90% |
~10% to ~20% |
Practical boundary: the coating system is not generic “ER polymer.” It is a two-polymer film defined by percent ranges of EC and HPMC, with a total coating fraction.
Expanded coating vs component allocation (Claims 8, 10, 11)
Claims 8 and 10-11 contain additional ranges tying the spheroid polymer/drug loading allocation to coating constraints. The most enforceable, clean quantitative anchors are the coating composition windows in Claims 5/7/9 and the core MCC/HPMC/venlafaxine windows in Claims 4/6/11/12.
How broad is claim coverage: formulation, method, or PK-outcome?
1) Claim 1 is outcome-tethered via PK (peak ≤ ~150 ng/mL)
This is the key boundary:
- Even if an infringing product contains ER venlafaxine HCl and is intended to last 24 hours, it must also produce:
- peak venlafaxine plasma levels ≤ about 150 ng/mL.
That PK ceiling creates room for designing around by changing exposure profile (peak shape, absorption rate, and release kinetics) while still giving “therapeutic” exposure over time.
2) Dependent claims make the formulation-specific scope real
Claim 1 sets the PK and dosing intent; Claims 3-12 then narrow to specific formulation architecture:
- spheroids made with MCC
- optional HPMC
- film coating with EC and HPMC in defined ratios
- with specific loading and coating weight fractions
Net effect: the strongest infringement posture exists when a competitor’s product matches both:
1) the PK peak constraint, and
2) the spheroid + EC/HPMC coating architecture.
What “diminished incidence of nausea and emesis” means for scope?
Claim 1 is a method with:
- a dosing regimen plus formulation,
- associated with a clinical outcome descriptor: “diminished incidence of nausea and emesis.”
For enforcement, that element functions as a claim limitation in the method context rather than purely a marketing statement. Still, the most objective constraint inside claim 1 is the peak plasma level cap.
What is the likely patent landscape structure around this asset?
A. US 6,403,120 sits in the “PK-optimized ER venlafaxine” cluster
This patent is positioned at the intersection of:
- ER formulation technology (spheroids, film coating)
- venlafaxine hydrochloride delivery
- toxicity-related GI side effects linked to plasma peak exposure
That cluster typically produces:
- multiple patents on formulation (spheroids/coat polymers)
- additional patents on dosage forms and release profiles
- sometimes separate patents on drug delivery methods or titration regimens.
B. Scope is constrained by quantification: peak and wt% ranges
The claim set is structured so that competitors cannot copy broadly; they must match quantified variables:
- Peak venlafaxine ≤ ~150 ng/mL
- Core composition: MCC-majority spheroid with optional HPMC
- Coating: EC/HPMC blend with specific ratio and total coating fraction
This style of claim drafting tends to support enforcement against close analogs but leaves gaps for more distant formulation systems that still achieve ER dosing.
C. Main design-around vectors
Using the claim boundaries as a map:
| Design variable |
How it can reduce infringement risk against 6,403,120 |
| Peak exposure |
shift release kinetics to raise or reshape peak beyond “≤ about 150 ng/mL” while maintaining tolerability |
| Coating polymer system |
replace EC/HPMC film stack or move polymer ratios outside EC 80-90% and HPMC 10-20% windows |
| Spheroid excipient system |
abandon MCC spheroid architecture or reduce matching MCC/HPMC/venlafaxine allocation |
| Encapsulation/spheroid format |
deploy ER format not built from spheroids, or not encapsulated in the claimed manner |
Where are the enforceability pressure points in the claim set?
Pressure point 1: “about 150 ng/mL” peak
Claim 1 uses “about,” which increases interpretive flexibility, but it remains a hard numeric constraint. The litigation posture for this kind of claim often turns on:
- measured PK profiles from relevant studies,
- sampling time points and assay methods,
- the definition of “peak” used by courts and experts.
Pressure point 2: EC/HPMC coating ratios
Claims 5/7/9 define:
- EC: 80-90 wt% of coating
- HPMC: 10-20 wt% of coating
- total coating: 2-12% of total formulation weight
Close variants that keep ER but alter coating chemistry or ratios can fall outside these ranges.
Pressure point 3: spheroid core composition ranges
Claims 4/6/11/12 define MCC and venlafaxine loading windows. If a product:
- uses MCC-like excipients but not MCC itself,
- changes HPMC usage to non-optional or removes it entirely,
- or changes venlafaxine loading outside specified windows,
it can attempt to avoid dependent claim coverage even if claim 1 remains a question.
Claim-by-claim scope map (what each adds)
| Claim |
Added limitation |
Scope impact |
| 1 |
Oral ER dosing; peak venlafaxine ≤ ~150 ng/mL over 24h; diminished nausea/emesis; venlafaxine HCl |
Defines core infringement thesis and the PK ceiling |
| 2 |
ER formulation encapsulated |
Narrows to encapsulated ER form |
| 3 |
ER formulation comprises venlafaxine HCl in spheroids with MCC (+ optional HPMC) |
Narrows to spheroid core architecture |
| 4 |
Core composition wt% windows (venlafaxine 6-40; MCC 50-94; optional HPMC 0.25-1) |
Narrows further into tunable design window |
| 5 |
Core film coating wt% 2-12; coating EC 80-90 and HPMC 10-20 |
Locks coating system constraints |
| 6 |
Preferred core window (venlafaxine 30-40; MCC 50-70; optional HPMC 0.25-1) |
Narrows to mid-high drug loading spheroids |
| 7 |
Preferred coating window consistent with claim 5 |
Reinforces coating constraints |
| 8 |
Additional composition windows tied to spheroid and coating framework |
Narrows variant space |
| 9 |
Reinforces coating windows in claim 5/7 |
Coating lock-in |
| 10 |
Additional formulation ratio windows (venlafaxine 5-25; MCC 95-75; optional HPMC) |
Narrows further on core allocation |
| 11 |
Core window (venlafaxine 6-25; MCC 94-75; optional HPMC) |
Tightens core composition |
| 12 |
Tighter core window (venlafaxine 6-20; MCC 94-80; optional HPMC) |
Tightest core subset among these |
| 13 |
ER formulation is venlafaxine HCl in spheroid |
Spheroid requirement version |
| 14 |
Encapsulated spheroid |
Encapsulation + spheroid requirement version |
Business implications: what to test for in competitor products
A structured infringement screen for a product marketed as ER venlafaxine should check:
- PK peak: does venlafaxine peak in the relevant population exceed “about 150 ng/mL” under typical dosing?
- Dosage-form architecture: is the ER solid built from spheroids?
- Core excipients: is microcrystalline cellulose used in the spheroid core in the claimed wt% windows (with optional HPMC)?
- Film coating system: does the product use an EC/HPMC film blend with EC 80-90% and HPMC 10-20% of coating, and total coating 2-12%?
Key Takeaways
- US 6,403,120 claims an oral ER method for venlafaxine HCl delivering 24-hour exposure with a peak ≤ about 150 ng/mL, tied to reduced nausea and emesis.
- Dependent claims require a spheroid-based ER system built from venlafaxine HCl + microcrystalline cellulose (optional HPMC) with a film coating of ethyl cellulose (NF) and HPMC (USP) in defined weight and ratio ranges.
- The patent’s enforceable scope is strongest when a competitor matches both the PK peak limitation and the EC/HPMC coated MCC spheroid construction.
- Main design-around levers are: peak exposure profile, coating polymer composition/ratios, and spheroid core excipient architecture.
FAQs
1) Does US 6,403,120 cover any ER venlafaxine product?
No. Claim 1 requires an ER formulation that produces a venlafaxine peak ≤ about 150 ng/mL over 24 hours, and dependent claims require specific spheroid and coating composition.
2) Is the clinical outcome (nausea/emesis reduction) a separate compound or just an outcome descriptor?
It is a method limitation attached to the dosing/formulation outcome descriptor in claim 1, paired with the objective peak plasma constraint.
3) What excipients are structurally central to the dependent claims?
The core spheroids rely on microcrystalline cellulose with optional hydroxypropylmethylcellulose (HPMC); the film coating uses ethyl cellulose (NF) and HPMC (USP).
4) What coating parameters are most specific in the claim set?
Total film coating 2-12% of formulation weight, with coating composition EC 80-90 wt% and HPMC 10-20 wt%.
5) What is the most direct design-around target?
The most direct target is the PK peak cap in claim 1 and, for dependent claims, the EC/HPMC coating ratio and the MCC-based spheroid core loading windows.
References
[1] United States Patent 6,403,120. “Method for providing therapeutic blood plasma concentration of venlafaxine over a twenty four hour period with diminished incidence of nausea and emesis.” Claims (as provided).
